News
Scotland approves MS drug that was rejected in England and Wales
BMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n391 (Published 09 February 2021) Cite this as: BMJ 2021;372:n391- Bryan Christie
- Edinburgh, UK
A drug that can reduce the number of relapses suffered by people with multiple sclerosis (MS) has been approved for use in Scotland despite a provisional decision to reject it in England and Wales.
Ozanimod (Zeposia) is a daily tablet that has been shown in a two year clinical trial to reduce relapses by around 38% compared with an existing treatment, injectable β …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £157 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£30 / $37 / €33 (excludes VAT)
You can download a PDF version for your personal record.